论文部分内容阅读
目的探讨瑞舒伐他汀对急性ST段抬高型心肌梗死(ASTEMI)患者经皮冠状动脉介入治疗(PCI)术后的影响。方法选取2013年2月—2015年2月山东大学齐鲁医院收治的ASTEMI患者204例,随机分为对照组和观察组,各102例。两组患者均行PCI,对照组患者给予常规药物治疗,观察组患者在对照组基础上加用瑞舒伐他汀。比较两组患者实验室检查指标、心功能指标、不良反应发生情况及满意度。结果治疗前两组患者血浆总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、内皮素(ET-1)、N-末端脑钠肽前体(NT-pro BNP)水平及血清一氧化氮(NO)、超敏C反应蛋白(hs-CRP)、补体3(C3)水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血浆TC、TG、LDL-C、ET-1、NT-pro BNP水平及血清NO、hs-CRP、C3水平低于对照组,血浆HDL-C水平高于对照组(P<0.05)。治疗后,两组患者血浆TC、TG、LDL-C、HDL-C、ET-1、NT-pro BNP水平及血清NO、hs-CRP、C3水平低于治疗前,血浆HDL-C水平高于治疗前(P<0.05)。治疗前两组患者左心室射血分数(LVEF)、左心室舒张末期的内径(LVEDD)、左房室瓣舒张期E峰和A峰比值(E/A比值)比较,差异无统计学意义(P>0.05);治疗后观察组患者LVEF高于对照组,LVEDD、E/A比值低于对照组(P<0.05);治疗后两组患者LVEF高于治疗前,LVEDD、E/A比值低于治疗前(P<0.05)。观察组患者不良反应发生率低于对照组,满意度高于对照组(P<0.05)。结论瑞舒伐他汀可有效改善ASTEMI患者PCI术后实验室检查指标和心功能指标,且不良反应较少,患者满意度较高。
Objective To investigate the effect of rosuvastatin on patients with acute ST-segment elevation myocardial infarction (ASTEMI) after percutaneous coronary intervention (PCI). Methods Totally 204 patients with ASTEMI admitted to Qilu Hospital of Shandong University from February 2013 to February 2015 were randomly divided into control group and observation group, with 102 cases in each group. Two groups of patients underwent PCI, the control group of patients given conventional drug treatment, the observation group patients in the control group based on the use of rosuvastatin. The laboratory test indexes, cardiac function indexes, the incidence of adverse reactions and satisfaction were compared between the two groups. Results The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), endothelin (ET- The levels of N-terminal pro-brain natriuretic peptide (NT-pro BNP) and serum nitric oxide (NO), hs-CRP and C3 were not significantly different (P > 0.05). The levels of TC, TG, LDL-C, ET-1, NT-pro BNP and NO, hs-CRP and C3 in the observation group were lower than those in the control group Group (P <0.05). After treatment, the level of plasma TC, TG, LDL-C, HDL-C, ET-1 and NT-pro BNP and the level of serum NO, hs-CRP and C3 in the two groups were lower than those before treatment Before treatment (P <0.05). There was no significant difference in left ventricular ejection fraction (LVEF), left ventricular end diastolic dimension (LVEDD), left ventricular diastolic E peak and A peak ratio (E / A ratio) between the two groups before treatment (P> 0.05). After treatment, the LVEF in the observation group was higher than that in the control group, and the LVEDD and E / A ratios were lower than those in the control group (P <0.05). After treatment, LVEF in the two groups was higher than that before treatment, LVEDD and E / A ratio Before treatment (P <0.05). The incidence of adverse reactions in observation group was lower than that in control group, and the satisfaction was higher than that in control group (P <0.05). Conclusions Rosuvastatin can effectively improve the laboratory and cardiac function after PCI in ASTEMI patients with less adverse reactions and higher patient satisfaction.